170 related articles for article (PubMed ID: 10501566)
1. Vasopressin(4-9) fragment activates V1a-type vasopressin receptor in rat supraoptic neurones.
Gouzènes L; Dayanithi G; Moos FC
Neuroreport; 1999 Jun; 10(8):1735-9. PubMed ID: 10501566
[TBL] [Abstract][Full Text] [Related]
2. V1a- and V2-type vasopressin receptors mediate vasopressin-induced Ca2+ responses in isolated rat supraoptic neurones.
Gouzénes L; Sabatier N; Richard P; Moos FC; Dayanithi G
J Physiol; 1999 Jun; 517 ( Pt 3)(Pt 3):771-9. PubMed ID: 10358117
[TBL] [Abstract][Full Text] [Related]
3. L-, N- and T- but neither P- nor Q-type Ca2+ channels control vasopressin-induced Ca2+ influx in magnocellular vasopressin neurones isolated from the rat supraoptic nucleus.
Sabatier N; Richard P; Dayanithi G
J Physiol; 1997 Sep; 503 ( Pt 2)(Pt 2):253-68. PubMed ID: 9306270
[TBL] [Abstract][Full Text] [Related]
4. Interplay between presynaptic and postsynaptic activities is required for dendritic plasticity and synaptogenesis in the supraoptic nucleus.
Chevaleyre V; Moos FC; Desarménien MG
J Neurosci; 2002 Jan; 22(1):265-73. PubMed ID: 11756510
[TBL] [Abstract][Full Text] [Related]
5. Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity.
Méchaly I; Laurent F; Portet K; Serrano J; Cros G
Eur J Pharmacol; 1999 Nov; 383(3):287-90. PubMed ID: 10594321
[TBL] [Abstract][Full Text] [Related]
6. Nonpeptide antagonists for vasopressin receptors. Pharmacology of SR 121463A, a new potent and highly selective V2 receptor antagonist.
Serradeil-Le Gal C
Adv Exp Med Biol; 1998; 449():427-38. PubMed ID: 10026834
[TBL] [Abstract][Full Text] [Related]
7. Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists.
Perucca J; Bichet DG; Bardoux P; Bouby N; Bankir L
J Am Soc Nephrol; 2008 Sep; 19(9):1721-31. PubMed ID: 18596120
[TBL] [Abstract][Full Text] [Related]
8. Effect of small molecule vasopressin V1a and V2 receptor antagonists on brain edema formation and secondary brain damage following traumatic brain injury in mice.
Krieg SM; Sonanini S; Plesnila N; Trabold R
J Neurotrauma; 2015 Feb; 32(4):221-7. PubMed ID: 25111427
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers.
Brouard R; Laporte V; Serradeil Le Gal C; Pignol R; Jang H; Donat F; Lockwood G; Fournie D; Dreux F
Adv Exp Med Biol; 1998; 449():455-65. PubMed ID: 10026839
[TBL] [Abstract][Full Text] [Related]
10. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.
Serradeil-Le Gal C; Lacour C; Valette G; Garcia G; Foulon L; Galindo G; Bankir L; Pouzet B; Guillon G; Barberis C; Chicot D; Jard S; Vilain P; Garcia C; Marty E; Raufaste D; Brossard G; Nisato D; Maffrand JP; Le Fur G
J Clin Invest; 1996 Dec; 98(12):2729-38. PubMed ID: 8981918
[TBL] [Abstract][Full Text] [Related]
11. [Arg8]-vasopressin-induced increase in intracellular Ca2+ concentration in cultured rat hippocampal neurons.
Mihara T; Tarumi T; Sugimoto Y; Chen Z; Kamei C
Brain Res Bull; 1999 Jul; 49(5):343-7. PubMed ID: 10452354
[TBL] [Abstract][Full Text] [Related]
12. Effect of SR-49059, a vasopressin V1a antagonist, on human vascular smooth muscle cells.
Serradeil-Le Gal C; Herbert JM; Delisee C; Schaeffer P; Raufaste D; Garcia C; Dol F; Marty E; Maffrand JP; Le Fur G
Am J Physiol; 1995 Jan; 268(1 Pt 2):H404-10. PubMed ID: 7840290
[TBL] [Abstract][Full Text] [Related]
13. Electrophysiological effects of kainic acid on vasopressin-enhanced green fluorescent protein and oxytocin-monomeric red fluorescent protein 1 neurones isolated from the supraoptic nucleus in transgenic rats.
Ohkubo J; Ohbuchi T; Yoshimura M; Maruyama T; Ishikura T; Matsuura T; Suzuki H; Ueta Y
J Neuroendocrinol; 2014 Jan; 26(1):43-51. PubMed ID: 24341559
[TBL] [Abstract][Full Text] [Related]
14. Lack of effect of a selective vasopressin V1A receptor antagonist SR 49,059, on potentiation by vasopressin of adrenoceptor-mediated pressor responses in the rat mesenteric arterial bed.
Heinemann A; Horina G; Stauber RE; Pertl C; Holzer P; Peskar BA
Br J Pharmacol; 1998 Nov; 125(6):1120-7. PubMed ID: 9863637
[TBL] [Abstract][Full Text] [Related]
15. Vasopressin-induced intracellular Ca2+ increase in isolated rat supraoptic cells.
Dayanithi G; Widmer H; Richard P
J Physiol; 1996 Feb; 490 ( Pt 3)(Pt 3):713-27. PubMed ID: 8683470
[TBL] [Abstract][Full Text] [Related]
16. A rise in the intracellular Ca2+ concentration of isolated rat supraoptic cells in response to oxytocin.
Lambert RC; Dayanithi G; Moos FC; Richard P
J Physiol; 1994 Jul; 478 ( Pt 2)(Pt 2):275-87. PubMed ID: 7525943
[TBL] [Abstract][Full Text] [Related]
17. Vascular effects of [Arg8]vasopressin in the isolated perfused rat kidney.
Barthelmebs M; Krieger JP; Grima M; Nisato D; Imbs JL
Eur J Pharmacol; 1996 Oct; 314(3):325-32. PubMed ID: 8957254
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.
Tahara A; Saito M; Sugimoto T; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
Br J Pharmacol; 1998 Dec; 125(7):1463-70. PubMed ID: 9884074
[TBL] [Abstract][Full Text] [Related]
19. Effect of a new, potent, non-peptide V1a vasopressin antagonist, SR 49059, on the binding and the mitogenic activity of vasopressin on Swiss 3T3 cells.
Serradeil-Le Gal C; Bourrié B; Raufaste D; Carayon P; Garcia C; Maffrand JP; Le Fur G; Casellas P
Biochem Pharmacol; 1994 Feb; 47(4):633-41. PubMed ID: 8129742
[TBL] [Abstract][Full Text] [Related]
20. Acute and chronic hyperglycemic effects of vasopressin in normal rats: involvement of V
Taveau C; Chollet C; Bichet DG; Velho G; Guillon G; Corbani M; Roussel R; Bankir L; Melander O; Bouby N
Am J Physiol Endocrinol Metab; 2017 Mar; 312(3):E127-E135. PubMed ID: 27998960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
